TNFRSF9 and neoplasm: Targeting 4-1BB in tumor models representing liver cancer, floor of mouth squamous cell cancer, colorectal cancer and lymphoma, using monoclonal antibodies (mAb) or recombinant 4-1BBL has generated robust anti-tumor responses (77–80).